Acute liver failure

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Acute liver failure (ALF), also known as fulminant hepatitis, is the final common pathway of severe hepatocyte injury, regardless of cause, and remains one of the most enigmatic and frightening conditions in all of medicine. Defined by the onset of altered mental status (hepatic encephalopathy) and coagulopathy (prolonged prothrombin time) occurring within 8 weeks of initial symptoms, ALF is estimated to affect 2000 individuals annually in the United States, only 200-300 of whom receive liver transplants. The rapidity of the course of ALF often catches clinicians off guard. The ALF syndrome is characterized by the unique clinical features of cerebral edema and shock with poor tissue oxygenation, shared by all causes. Over 50% of ALF cases in the United States are now due to drug hepatotoxicity, either acetaminophen-related or caused by idiosyncratic drug reactions. The very high mortality observed in past decades has improved because of better intensive care, the advent of transplantation, and an increase in the number of acetaminophen cases that carry a good prognosis. However, hepatic transplantation is often inappropriate or unavailable. Even at transplant centers, only 29% of patients receive a liver graft, and 38% survive without transplantation. The mainstay of ALF management remains skilled intensive care focused on the specific problems of these patients. Liver support machines have not yet come of age. Because a large proportion of patients never receive a liver graft, renewed efforts to understand ALF itself make sense, with the goal of preserving remaining hepatocytes or regenerating the failing liver.

Original languageEnglish (US)
Pages (from-to)101-110
Number of pages10
JournalClinical Perspectives in Gastroenterology
Volume4
Issue number2
StatePublished - 2001

Fingerprint

Acute Liver Failure
Liver
Transplants
Critical Care
Acetaminophen
Hepatocytes
Transplantation
Hepatic Encephalopathy
Prothrombin Time
Brain Edema
Pharmaceutical Preparations
Liver Transplantation
Hepatitis
Shock
Medicine
Mortality
Wounds and Injuries

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Acute liver failure. / Lee, W. M.

In: Clinical Perspectives in Gastroenterology, Vol. 4, No. 2, 2001, p. 101-110.

Research output: Contribution to journalArticle

@article{672d9cd9765a43e5b539ebc0bea4ac60,
title = "Acute liver failure",
abstract = "Acute liver failure (ALF), also known as fulminant hepatitis, is the final common pathway of severe hepatocyte injury, regardless of cause, and remains one of the most enigmatic and frightening conditions in all of medicine. Defined by the onset of altered mental status (hepatic encephalopathy) and coagulopathy (prolonged prothrombin time) occurring within 8 weeks of initial symptoms, ALF is estimated to affect 2000 individuals annually in the United States, only 200-300 of whom receive liver transplants. The rapidity of the course of ALF often catches clinicians off guard. The ALF syndrome is characterized by the unique clinical features of cerebral edema and shock with poor tissue oxygenation, shared by all causes. Over 50{\%} of ALF cases in the United States are now due to drug hepatotoxicity, either acetaminophen-related or caused by idiosyncratic drug reactions. The very high mortality observed in past decades has improved because of better intensive care, the advent of transplantation, and an increase in the number of acetaminophen cases that carry a good prognosis. However, hepatic transplantation is often inappropriate or unavailable. Even at transplant centers, only 29{\%} of patients receive a liver graft, and 38{\%} survive without transplantation. The mainstay of ALF management remains skilled intensive care focused on the specific problems of these patients. Liver support machines have not yet come of age. Because a large proportion of patients never receive a liver graft, renewed efforts to understand ALF itself make sense, with the goal of preserving remaining hepatocytes or regenerating the failing liver.",
author = "Lee, {W. M.}",
year = "2001",
language = "English (US)",
volume = "4",
pages = "101--110",
journal = "Clinical Gastroenterology and Hepatology",
issn = "1542-3565",
publisher = "W.B. Saunders Ltd",
number = "2",

}

TY - JOUR

T1 - Acute liver failure

AU - Lee, W. M.

PY - 2001

Y1 - 2001

N2 - Acute liver failure (ALF), also known as fulminant hepatitis, is the final common pathway of severe hepatocyte injury, regardless of cause, and remains one of the most enigmatic and frightening conditions in all of medicine. Defined by the onset of altered mental status (hepatic encephalopathy) and coagulopathy (prolonged prothrombin time) occurring within 8 weeks of initial symptoms, ALF is estimated to affect 2000 individuals annually in the United States, only 200-300 of whom receive liver transplants. The rapidity of the course of ALF often catches clinicians off guard. The ALF syndrome is characterized by the unique clinical features of cerebral edema and shock with poor tissue oxygenation, shared by all causes. Over 50% of ALF cases in the United States are now due to drug hepatotoxicity, either acetaminophen-related or caused by idiosyncratic drug reactions. The very high mortality observed in past decades has improved because of better intensive care, the advent of transplantation, and an increase in the number of acetaminophen cases that carry a good prognosis. However, hepatic transplantation is often inappropriate or unavailable. Even at transplant centers, only 29% of patients receive a liver graft, and 38% survive without transplantation. The mainstay of ALF management remains skilled intensive care focused on the specific problems of these patients. Liver support machines have not yet come of age. Because a large proportion of patients never receive a liver graft, renewed efforts to understand ALF itself make sense, with the goal of preserving remaining hepatocytes or regenerating the failing liver.

AB - Acute liver failure (ALF), also known as fulminant hepatitis, is the final common pathway of severe hepatocyte injury, regardless of cause, and remains one of the most enigmatic and frightening conditions in all of medicine. Defined by the onset of altered mental status (hepatic encephalopathy) and coagulopathy (prolonged prothrombin time) occurring within 8 weeks of initial symptoms, ALF is estimated to affect 2000 individuals annually in the United States, only 200-300 of whom receive liver transplants. The rapidity of the course of ALF often catches clinicians off guard. The ALF syndrome is characterized by the unique clinical features of cerebral edema and shock with poor tissue oxygenation, shared by all causes. Over 50% of ALF cases in the United States are now due to drug hepatotoxicity, either acetaminophen-related or caused by idiosyncratic drug reactions. The very high mortality observed in past decades has improved because of better intensive care, the advent of transplantation, and an increase in the number of acetaminophen cases that carry a good prognosis. However, hepatic transplantation is often inappropriate or unavailable. Even at transplant centers, only 29% of patients receive a liver graft, and 38% survive without transplantation. The mainstay of ALF management remains skilled intensive care focused on the specific problems of these patients. Liver support machines have not yet come of age. Because a large proportion of patients never receive a liver graft, renewed efforts to understand ALF itself make sense, with the goal of preserving remaining hepatocytes or regenerating the failing liver.

UR - http://www.scopus.com/inward/record.url?scp=0035080153&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035080153&partnerID=8YFLogxK

M3 - Article

VL - 4

SP - 101

EP - 110

JO - Clinical Gastroenterology and Hepatology

JF - Clinical Gastroenterology and Hepatology

SN - 1542-3565

IS - 2

ER -